Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis.
This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.

开始日期2015-04-22

申办/合作机构

Memorial Sloan Kettering Cancer Center

100 项与甲氯芬那酸钠相关的临床结果

登录后查看更多信息

100 项与甲氯芬那酸钠相关的转化医学

登录后查看更多信息

100 项与甲氯芬那酸钠相关的专利（医药）

登录后查看更多信息

1,701

项与甲氯芬那酸钠相关的文献（医药）

2026-04-01·BIOCHEMICAL PHARMACOLOGY

Inhibition of Ca2+-activated chloride channels by the NSAID meclofenamate for anti-diarrhea

Article

作者: Wang, KeWei ; Zhou, Ping ; Li, Xiangyu ; Shi, Huan ; Li, Qinqin ; Liu, Yani

Dysfunctional calcium-activated chloride channels (CaCCs) are implicated in many pathological phenotypes and diseases. The CaCC ANO1/TMEM16A robustly expressed in epithelial cells plays an essential role in regulation of Cl^- secretion and intestinal motility. In this study, we investigated the effects of a nonsteroidal anti-inflammatory drug (NSAID) meclofenamate on ANO1 channel and dextran sulfate sodium (DSS)-induced diarrhea in mice. Meclofenamate inhibits CaCC ANO1 channel in a concentration-dependent manner with an IC₅₀ of 16.2 ± 2.7 μM. Meclofenamate also reduces single-channel open probability without altering the channel conductance. Molecular docking and site-directed mutagenesis demonstrate that residues R515, R535 and E654 are important for meclofenamate-mediated ANO1 inhibition. Selectivity evaluation demonstrates that meclofenamate also inhibits other CaCCs, including ANO2, ANO6 and Bestrophin-1 with IC₅₀ values ranging from approximately 10 to 20 μM. Further in vivo experiments show that meclofenamate dose-dependently reduces intestinal peristalsis and diarrhea induced by DSS in mice. Altogether, our findings reveal a novel role of meclofenamate in inhibiting CaCC currents and alleviating DSS-induced acute diarrhea, thus holding repurposing potential for therapy of diarrhea or gastrointestinal dysfunction.

2026-02-01·MOLECULAR PSYCHIATRY

Next-generation precision medicine for pain

Article

作者: Niculescu, A B ; Shekhar, A ; Bhagar, R ; Gettelfinger, A S ; Matei, E ; Woods, C ; Mullen, J ; Ebushi, A ; Schmitz, M ; Le-Niculescu, H ; Kurian, S M ; Corey, S C ; White, F A

Chronic pain remains a massive problem in society in general, and in mental health patients in particular, being strongly bi-directionally connected to mental health. Lack of widespread use of objective information has hampered treatment and prevention efforts. Pain is a spectrum of severity, from transient vague discomfort to chronic excruciating incapacitation. Blood biomarkers that track pain severity can provide a window into the biology of pain, as well as could help with assessment and treatment. A previous study by us was positive. Here we describe new studies we conducted trans-diagnostically in psychiatric patients, starting with the whole genome, to expand the identification, prioritization, validation and testing of blood gene expression biomarkers for pain. We carried out two separate studies, on two different platforms, microarrays and RNA sequencing, using for each study a multiple independent cohorts design. This ensured biological and technical reproducibility. We then focused at the end on biomarkers that were convergent and reproducible between the two studies. We found new as well as previously known biomarkers that were predictive of high pain states, and of future emergency department visits related to them, using cross-sectional and longitudinal approaches. Using a polyevidence score, the overall top decreased in expression biomarker ("pain-suppressor gene") was CD55, a gene that suppresses the complement cascade and cell damage. The top increased biomarker ("algogene") was ANXA1, a gene that is an effector of glucocorticoid-mediated responses and regulator of the inflammatory processes. The top biological pathways were related to cellular response to TNF and to neuroinflammation. The top upstream regulator was TNF. Top therapeutic matches overall were the medications lithium and ketamine, as well as the nutraceuticals omega-3 fatty acids and magnesium. Drug repurposing bioinformatic analyses also identified the potential of carvedilol, sirolimus, budesonide, berbamine, and quetiapine, as well as of medications already used to treat pain such as amyleine, sulindac, sufentanil, carbamazepine, and meclofenamic acid, that serve as de facto positive controls. Additionally, we show how personalized patient reports for doctors would look like based on blood biomarkers testing, to aid with objective assessment of severity and risk, as well with individualized matching to medications and nutraceuticals. Given the fact that pain disorders are highly prevalent, can severely affect quality of life, and even lifespan, there is an urgent need for insights and tools such as the ones we have developed to be applied to and improve clinical diagnosis, treatment, and prevention options.

2026-02-01·JOURNAL OF CONTAMINANT HYDROLOGY

Fate, chlorination kinetics, and comprehensive risk assessment of pharmaceuticals and personal care products in drinking water distribution systems

Article

作者: Wang, Fei ; Xiao, Minru ; Wei, Anlei ; Li, Nan ; Li, Zhenglin

The widespread occurrence of pharmaceuticals and personal care products (PPCPs) in aquatic environments has emerged as a global concern due to their potential threats to water security and ecological health. Despite increasing attention, their fate and associated risks in drinking water systems remain insufficiently understood. The occurrence, transformation behavior, and ecological and human health risks of 19 PPCPs were investigated across drinking water treatment and distribution systems in this study. Eighteen PPCPs were ubiquitously detected in raw water, with high detection frequencies (>70 %), whereas both the number of detected compounds and their concentrations were markedly reduced in finished water (five compounds) and tap water (eleven compounds). These results demonstrate the substantial effectiveness of conventional treatment processes in reducing both the diversity and concentrations of PPCPs. To further elucidate their potential transformation during water treatment, chlorination kinetics of eight structurally diverse PPCPs were evaluated under controlled conditions. Four compounds (atenolol, sulpiride, paroxetine, and nadolol) exhibited pseudo-first-order kinetics with residual chlorine, while the others exhibited significant resistance to chlorination. Degradation efficiency was found to depend on both the water matrix conditions and their molecular properties, highlighting the combined roles of intrinsic chemical properties and environmental complexity. Ecological risk assessment revealed ibuprofen posed a moderate ecological risk, a risk quotient (RQ) of 0.335, while triclocarban presented a high ecological risk (RQ = 4.6031). Mixture toxicity assessment based on the cumulative toxic unit (ΣTU) further indicated a potential ecological risk (ΣTU > 1) in raw water. Human health risk assessment showed minimal risks across all age groups (RQ 〈10^-3). However, infants were identified as the most susceptible population, likely due to their higher exposure relative to body weight. Among the detected PPCPs, meclofenamic acid was identified as the compound of highest concern, with average relative risk indices exceeding >10^-4. These findings provide critical insights into the fate and transformation of PPCPs in drinking water systems and offer scientific guidance for optimizing treatment processes and risk management strategies.

项与甲氯芬那酸钠相关的新闻（医药）

2023-07-26

·PRNewswire

Sahmyook University Study Repurposes Meclofenamate to Treat Abnormal Respiratory Mucus

Korean researchers have shown that meclofenamate is a promising drug for controlling mucin levels in the respiratory mucus SEOUL, South Korea, July 26, 2023 /PRNewswire/ -- Our respiratory system is lined with a thin fluid layer called mucus on the inside. The mucus protects us from inhaling harmful and unwanted airborne agents from germs to pollutants; it achieves this feat due to its unique gel-like texture imparted by proteins called mucins. By extension, over- or under-secretion of mucins can lead to abnormal respiratory mucus—a pathological manifestation in many respiratory diseases like chronic bronchitis, cystic fibrosis, and asthma, among others. Although multiple clinically approved drugs are available that can combat abnormal respiratory mucus, many of them cause unwanted and potentially serious side effects. This calls for an alternative solution to provide relief to patients having respiratory diseases. Continue Reading Korean researchers repurpose a nonsteroidal anti-inflammatory drug called meclofenamate to treat the culprit in many respiratory diseases, namely abnormal mucus. In a recent study, a group of researchers from Korea repurposed an available drug called meclofenamate to understand its effects on the respiratory mucus. Meclofenamate had been traditionally used as a nonsteroidal anti-inflammatory drug for treating arthritis, parasitic infections, and prostate cancer, among other diseases. The researchers have now found that meclofenamate can also treat abnormal respiratory mucus by controlling mucin secretion. Their study was made available online on April 7, 2023, and was published in Volume 31 Issue 3 of the journal, Biomolecules & Therapeutics, in March 13, 2023. Speaking about the clinical potential of the results of the study, Dr. Hyun-Jae Lee, who is an associate professor at Smith Liberal Arts College and Department of Addiction Science, Graduate School, Sahmyook University, and one of the lead researchers exclaims, "Compared to conventional drug development strategies, our strategy of discovering new therapeutic effects from existing drugs saves a lot of time and costs." How indeed did Dr. Lee and his team go about this landmark study? The researchers tested the meclofenamate in a cell line called NCI-H292 that mimicked the respiratory cells, replete with the secretion of mucus with mucins. Specifically, they checked for the expression of a gene responsible for secreting a key mucin, MUC5AC. Further, they explored the molecular pathways involved in the action of meclofenamate on the mucin. Their findings hit the bull's eye, to say the least. Their results suggested that meclofenamate markedly reduced the gene and, additionally, the protein expression of MUC5AC. The drug was found to achieve this by influencing a biomolecular pathway that is extensively involved in the immune response, namely the nuclear factor kappa light chain enhancer of activated B (or NF-kB) cell signaling pathway; it reduced the degradation of a biomolecular component called 'inhibitory kappa Bα' and the movement of another such component called 'p65' into the nucleus of the respiratory cells. The gist of these findings is clear—meclofenamate is capable of controlling mucin secretion, and in turn, the characteristics of respiratory mucus. Without doubt, meclofenamate has emerged as a novel therapeutic agent for abnormal respiratory mucus, with this study. These findings not only succeed in repurposing a readily available and clinically approved drug for a new disease condition, but also sets an example for ongoing efforts related to drug development and research. Reference Title of original paper: Meclofenamate Suppresses MUC5AC Mucin Gene Expression by Regulating the NF-kB Signaling Pathway in Human Pulmonary Mucoepidermoid NCI-H292 Cells Journal: Biomolecules & Therapeutics DOI: About Sahmyook University Website: Contact: Eunyoung Eom 02-3399-3928 [email protected]com SOURCE Sahmyook University

临床结果

2023-04-17

·drugs

Get Pain Relief With the Most Common Arthritis Medications

MONDAY, April 17, 2023 -- Arthritis is a common disease that causes pain and inflammation in different body joints, making it difficult to enjoy everyday tasks and physical activity. Fortunately, there are many different medications for arthritis. Depending on what type of arthritis you have and its severity, an arthritis medication may help you manage pain and other symptoms. Here is a breakdown of the most common arthritis medications, how they work and their potential side effects. The Arthritis Foundation lists the following as the medications used to treat arthritis: Analgesics including acetaminophen (Tylenol) and opioids Nonsteroidal anti-inflammatory drugs (NSAIDs) Corticosteroids Disease-modifying antirheumatic drugs (DMARDs) including biologics and targeted DMARDs Analgesics The Arthritis Foundation reports that analgesics may help with mild to moderate pain, but they will not help with the inflammation associated with arthritis. Analgesics work in the nervous system and alter how your brain perceives pain. They can be used to treat the pain associated with any type of arthritis, although more effective options are available. Analgesics can be opioid, non-opioid or a combination. Common analgesics are: Acetaminophen (Tylenol) Codeine Oxycodone Fentanyl Hydrocodone Potential side effects: Kidney damage Liver damage Addiction Constipation Gastrointestinal bleeding Use caution when taking these medications; take only as prescribed. NSAIDs NSAIDs work by blocking prostaglandin. According to the Cleveland Clinic , one role prostaglandins play is forming clots and causing inflammation at the site of an injury. NSAIDs are used to treat the pain and inflammation associated with rheumatoid arthritis and osteoarthritis . Common over-the-counter (OTC) NSAIDs are: Aspirin (Bayer, St. Joseph, Anacin, Excedrin and more) Ibuprofen (Motrin, Advil) Naproxen sodium (Aleve) Prescription NSAIDs are: Celecoxib (Celebrex) Diclofenac (Voltaren, available by brand name in topical form) Fenoprofen (Nalfon) Indomethacin (Indocin, available by brand name in liquid form) Ketorolac tromethamine (Toradol) Meclofenamate sodium (Meclomen) Diflunisal (Dolobid) Tolmetin (Tolectin) Ketoprofen (Orudis) Flurbiprofen (Ansaid) Potential side effects of NSAIDs are: Increased risk of stomach and bowel issues like ulcers and bleeding Increased risk of stroke Heart problems Stomach pain Nausea Diarrhea/constipation Corticosteroids According to the Arthritis Foundation , corticosteroids mimic cortisol, a hormone your body produces naturally. They are used to treat inflammatory types of arthritis, including rheumatoid arthritis and psoriatic arthritis. They are great for short-term relief of inflammation but are not recommended for long-term use because of their side effects. Your doctor may prescribe a lower dose if you require them for long-term use. Common corticosteroids: Prednisone (Deltasone, Prednicot, Cotolone) Prednisolone (Orapred, Omnipred) Cortisone (Cortone) Hydrocortisone (Cortef, Hydrocort) Triamcinolone (Aristocort) Dexamethasone (Decadron) Common side effects of corticosteroids: Blood sugar spikes Weight gain Bone loss Risk of cataracts High blood pressure Infections Mood changes DMARDs The Arthritis Foundation says that DMARDs work with the body to “stop or slow the disease process in inflammatory forms of arthritis.” They work by blocking inflammation. There are many different DMARDs on the market, and they all have different ways of working in the body. Conventional DMARDs work by broadly suppressing the immune system. Often they are used in combination with other therapies. Targeted DMARDs block specific pathways inside immune cells. Biologic DMARDs are produced by live cells and work on specific immune proteins called cytokines. Common DMARDs: Apremilast (Otezla) Baricitinib (Olumiant) Cyclophosphamide (Cytoxan) Cyclosporine (Gengraf, Neoral) Hydroxychloroquine (Plaquenil) Leflunomide (Arava) Methotrexate (Otrexup, Rasuvo, RediTrex) Mycophenolate mofetil (CellCept) Sulfasalazine (Azulfidine) Tofacitinib (Xeljanz, Xeljanz XR) According to the Cleveland Clinic , common side effects of traditional DMARDs include: Loss of appetite Nausea Diarrhea Abdominal pain Rash, allergic reaction Liver problem Increased risk of infection Low blood cell counts Common side effects of biologic DMARDs include: Increased risk of common and serious infections Reactivation of tuberculosis, herpes zoster, and hepatitis B and C Increased cholesterol levels, increased liver enzymes and low blood cell counts Increased risk of clotting When prescribed DMARDs, inform your doctor of any other medications, including over-the-counter medicines, you are taking to avoid drug interactions. Some of these medications can cause teratogenicity (defects in a developing fetus.) Writing recently in the Journal of the American Academy of Physician Assistants (JAAPA ), physician assistant Michelle DiBiase and Dr. Samantha Kohn remind people that "The mainstay of pharmacologic therapy is early intervention with use of nonbiologic and biologic DMARDs together with adjunctive medications such as NSAIDs, oral and intra-articular corticosteroids, and analgesic medications, including opioids." Your primary care provider or rheumatologist will work closely with you to determine which medications are best for your treatment. It is vital to keep them apprised of any side effects and let them know if the treatment is ineffective. They can work with you to find a treatment that helps relieve the pain and inflammation caused by arthritis. Posted April 2023

上市批准

100 项与甲氯芬那酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00169	甲氯芬那酸钠	M01AG04 M02AA18	DBSALT001241

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
痛经	美国	Parke, Davis & Co. LLC	1980-06-25
骨关节炎	美国	Parke, Davis & Co. LLC	1980-06-25
疼痛	美国	Parke, Davis & Co. LLC	1980-06-25
类风湿关节炎	美国	Parke, Davis & Co. LLC	1980-06-25